Chief Financial Officer
Andrew Geall Ph.D.
Chief Scientific Officer
Padma Kodukula, Ph.D., MBA
Chief Business Officer
PNI Announces New Chief Scientific Officer Dr. Andy Geall
On April 8, 2020, we announced a major new addition to our arsenal of expertise. Dr. Andy Geall joined our team as Chief Scientific Officer.
Dr. Geall, who is renowned for leading the RNA nanoparticle vaccine platform at Novartis and was the Principal Investigator on a DARPA contract to apply the technology towards pandemic response. He demonstrated how a fully synthetic H7N9 flu vaccine was developed in less than 2 weeks upon sequencing. Read the press release here.
James Taylor, Ph.D.
Mira Chaurushiya, Ph.D.
Deval Lashkari, Ph.D.
Joe Victor, MBA
Yvonne Perrie Ph.D.
Professor, Strathclyde University, Glasgow Chair in Drug Delivery, Associate Dean of Research
Frank Slack Ph.D.
Professor Beth Israel Deaconess Medical Director of the Initiative for RNA Medicine at Harvard Medical School
Carl Hansen Ph.D.
Associate Professor UBC CEO & Co-Founder, AbCellera
Dan Peer Ph.D.
Managing Director SPARK Tel Aviv, Chair Tel Aviv University Cancer Biology Research Center, Director Laboratory of Precision NanoMedicine